2023-04-27 08:31:32 ET
- Clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, HCW Biologics ( NASDAQ: HCWB ) has a entered into a $26.25 M development line of credit agreement on April 21, 2023.
- This five-year, non-amortizing loan, collateralized with real estate assets, provides project financing for the buildout of the company’s new headquarters and manufacturing facility.
- The stock price has jumped about 19% on Thursday pre-market
For further details see:
HCW Biologics climbs 19% on $26.25M asset-backed development loan